Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | LSS | P48449 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229552 | 1.00 | CHRNA7 (0.68) | CHRNA7CYP1A2CYP2D6LSSALDH1A1 | |
| SCHEMBL13444725 | 0.95 | CHRNA7 (0.71) | CHRNA7CYP1A2CYP2D6LSSALDH1A1 | |
| SCHEMBL5396665 | 0.89 | CHRNA7 (0.64) | CHRNA7CYP1A2CYP2D6LSSALDH1A1 | |
| SCHEMBL6941982 | 0.86 | LSS (0.57) | CHRNA7LSSCHRM1 | |
| SCHEMBL5390772 | 0.86 | LSS (0.60) | CHRNA7LSS | |
| SCHEMBL3215152 | 0.83 | LSS (0.78) | CHRNA7LSSALDH1A1 | |
| SCHEMBL2323165 | 0.83 | LSS (0.57) | CHRNA7LSS | |
| SCHEMBL1849257 | 0.83 | LSS (0.57) | CHRNA7LSSCHRM1 | |
| SCHEMBL1542743 | 0.83 | LSS (0.57) | CHRNA7LSS | |
| SCHEMBL5652779 | 0.83 | LSS (0.57) | CHRNA7LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674794-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-03-09 | — | — | US | disclosed |
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | ARGENTA DISCOVERY LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| EP-2121688-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | Argenta Discovery Ltd (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008099186-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | ARGENTA DISCOVERY LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
| US-20070066592-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRNA7 2/4885CYP1A2 265/4885CYP2D6 892/4885 |
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | CHRM2, CHRM3, CHRM1 | CHRNA7 13/4885CYP1A2 603/4885CYP2D6 616/4885 |
| US-20070066592-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRNA7 2/4885CYP1A2 266/4885CYP2D6 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.